Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects
elderly individuals. Increase in incidence rates in the past decades has been attributed to …

Bullous pemphigoid (BP) is the most common autoimmune bullous disease, characterized
by severe pruritus and skin blistering. The loss of tolerance against Collagen XVII, also …

For many years, The Journal of Investigative Dermatology (JID) has been a leader in our
understanding of many aspects of the major autoimmune blistering skin diseases …

Highlights•Conventional immunosuppressive therapies in pemphigoid are associated with
increased morbidity and mortality.•Doxycycline has the potential of a suitable first line …

The rapid evolution of anti-cancer therapy (including chemotherapy, targeted therapy, and
immunotherapy) in recent years has led to a more favorable efficacy and safety profile for a …

Substitution of IgG in antibody deficiency or application of high-dose intravenous IgG in
patients with autoimmunity is a well-established treatment. However, data on the mode of …

We read with interest the article by Baffa et al.,[1] who reported a case of severe bullous
pemphigoid (BP) developed 10 days after the second dose of Pfizer/BioNtech BNT162b2 …

Abstract Background In Japan, intravenous immunoglobulin (IVIG) has been approved for
corticosteroid-unresponsive bullous pemphigoid (BP); however, its usage, efficacy, and …

El penfigoide ampolloso (PA) es una enfermedad autoinmune producida por la presencia
de autoanticuerpos dirigidos frente a BP180 y BP230. A pesar de ser la enfermedad …

Methods This retrospective cross-sectional study used Department of Defense TRICARE
data to determine factors associated with IVIg therapy among bullous pemphigoid patients …